Antinociception depends on the presence of G protein γ2- subunits in brain

Eva V. Varga, Keiko Hosohata, Dariusz Borys, Edita Navratilova, Anders Nylen, Todd W Vanderah, Frank Porreca, William R Roeske, Henry I. Yamamura

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We have shown previously [Hosohata, K., Logan, J.K., Varga, E., Burkey, T.H., Vanderah, T.W., Porreca, F., Hruby, V.J., Roeske, W.R., Yamamura, H.I., 2000. The role of the G protein γ2 subunit in opioid antinociception in mice. Eur. J. Pharmacol. 392, R9-R11] that intracerebroventricular (i.c.v.) treatment of mice with a phosphorothioate oligodeoxynucleotide antisense to the γ2 subunit (Gγ2) of the heterotrimeric G proteins (antisense ODN) significantly attenuates antinociception by a δ-opioid receptor agonist. In the present study, we examined the involvement of Gγ2 in antinociception mediated by other (μ- or κ-opioid, cannabinoid, α2-adrenoreceptor) analgesic agents in a warm (55°C) water tail-flick test in mice. Interestingly, i.c.v. treatment with the antisense ODN attenuated antinociception by each analgesic agent. Missense phosphorothioate oligodeoxynucleotide treatment, on the other hand, had no effect on antinociception mediated by these agonists. The antinociceptive response recovered in 6 days after the last antisense ODN injection, indicating a lack of nonspecific tissue damage in the animals. These results suggest a pervasive role for the G protein γ2 subunits in supraspinal antinociception.

Original languageEnglish (US)
Pages (from-to)93-98
Number of pages6
JournalEuropean Journal of Pharmacology
Volume508
Issue number1-3
DOIs
StatePublished - Jan 31 2005

Fingerprint

Protein Subunits
GTP-Binding Proteins
Oligodeoxyribonucleotides
Opioid Analgesics
Analgesics
Brain
Heterotrimeric GTP-Binding Proteins
Cannabinoids
Opioid Receptors
Tail
Therapeutics
Injections
Water

Keywords

  • Antinociception
  • Cannabinoid receptor agonist
  • Clonidine
  • G protein γ subunit
  • Guanine nucleotide binding protein
  • Opioid receptor agonist

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Varga, E. V., Hosohata, K., Borys, D., Navratilova, E., Nylen, A., Vanderah, T. W., ... Yamamura, H. I. (2005). Antinociception depends on the presence of G protein γ2- subunits in brain. European Journal of Pharmacology, 508(1-3), 93-98. https://doi.org/10.1016/j.ejphar.2004.11.062

Antinociception depends on the presence of G protein γ2- subunits in brain. / Varga, Eva V.; Hosohata, Keiko; Borys, Dariusz; Navratilova, Edita; Nylen, Anders; Vanderah, Todd W; Porreca, Frank; Roeske, William R; Yamamura, Henry I.

In: European Journal of Pharmacology, Vol. 508, No. 1-3, 31.01.2005, p. 93-98.

Research output: Contribution to journalArticle

Varga, Eva V. ; Hosohata, Keiko ; Borys, Dariusz ; Navratilova, Edita ; Nylen, Anders ; Vanderah, Todd W ; Porreca, Frank ; Roeske, William R ; Yamamura, Henry I. / Antinociception depends on the presence of G protein γ2- subunits in brain. In: European Journal of Pharmacology. 2005 ; Vol. 508, No. 1-3. pp. 93-98.
@article{6b05fb96c1cc459ab290d9c28891c1e4,
title = "Antinociception depends on the presence of G protein γ2- subunits in brain",
abstract = "We have shown previously [Hosohata, K., Logan, J.K., Varga, E., Burkey, T.H., Vanderah, T.W., Porreca, F., Hruby, V.J., Roeske, W.R., Yamamura, H.I., 2000. The role of the G protein γ2 subunit in opioid antinociception in mice. Eur. J. Pharmacol. 392, R9-R11] that intracerebroventricular (i.c.v.) treatment of mice with a phosphorothioate oligodeoxynucleotide antisense to the γ2 subunit (Gγ2) of the heterotrimeric G proteins (antisense ODN) significantly attenuates antinociception by a δ-opioid receptor agonist. In the present study, we examined the involvement of Gγ2 in antinociception mediated by other (μ- or κ-opioid, cannabinoid, α2-adrenoreceptor) analgesic agents in a warm (55°C) water tail-flick test in mice. Interestingly, i.c.v. treatment with the antisense ODN attenuated antinociception by each analgesic agent. Missense phosphorothioate oligodeoxynucleotide treatment, on the other hand, had no effect on antinociception mediated by these agonists. The antinociceptive response recovered in 6 days after the last antisense ODN injection, indicating a lack of nonspecific tissue damage in the animals. These results suggest a pervasive role for the G protein γ2 subunits in supraspinal antinociception.",
keywords = "Antinociception, Cannabinoid receptor agonist, Clonidine, G protein γ subunit, Guanine nucleotide binding protein, Opioid receptor agonist",
author = "Varga, {Eva V.} and Keiko Hosohata and Dariusz Borys and Edita Navratilova and Anders Nylen and Vanderah, {Todd W} and Frank Porreca and Roeske, {William R} and Yamamura, {Henry I.}",
year = "2005",
month = "1",
day = "31",
doi = "10.1016/j.ejphar.2004.11.062",
language = "English (US)",
volume = "508",
pages = "93--98",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Antinociception depends on the presence of G protein γ2- subunits in brain

AU - Varga, Eva V.

AU - Hosohata, Keiko

AU - Borys, Dariusz

AU - Navratilova, Edita

AU - Nylen, Anders

AU - Vanderah, Todd W

AU - Porreca, Frank

AU - Roeske, William R

AU - Yamamura, Henry I.

PY - 2005/1/31

Y1 - 2005/1/31

N2 - We have shown previously [Hosohata, K., Logan, J.K., Varga, E., Burkey, T.H., Vanderah, T.W., Porreca, F., Hruby, V.J., Roeske, W.R., Yamamura, H.I., 2000. The role of the G protein γ2 subunit in opioid antinociception in mice. Eur. J. Pharmacol. 392, R9-R11] that intracerebroventricular (i.c.v.) treatment of mice with a phosphorothioate oligodeoxynucleotide antisense to the γ2 subunit (Gγ2) of the heterotrimeric G proteins (antisense ODN) significantly attenuates antinociception by a δ-opioid receptor agonist. In the present study, we examined the involvement of Gγ2 in antinociception mediated by other (μ- or κ-opioid, cannabinoid, α2-adrenoreceptor) analgesic agents in a warm (55°C) water tail-flick test in mice. Interestingly, i.c.v. treatment with the antisense ODN attenuated antinociception by each analgesic agent. Missense phosphorothioate oligodeoxynucleotide treatment, on the other hand, had no effect on antinociception mediated by these agonists. The antinociceptive response recovered in 6 days after the last antisense ODN injection, indicating a lack of nonspecific tissue damage in the animals. These results suggest a pervasive role for the G protein γ2 subunits in supraspinal antinociception.

AB - We have shown previously [Hosohata, K., Logan, J.K., Varga, E., Burkey, T.H., Vanderah, T.W., Porreca, F., Hruby, V.J., Roeske, W.R., Yamamura, H.I., 2000. The role of the G protein γ2 subunit in opioid antinociception in mice. Eur. J. Pharmacol. 392, R9-R11] that intracerebroventricular (i.c.v.) treatment of mice with a phosphorothioate oligodeoxynucleotide antisense to the γ2 subunit (Gγ2) of the heterotrimeric G proteins (antisense ODN) significantly attenuates antinociception by a δ-opioid receptor agonist. In the present study, we examined the involvement of Gγ2 in antinociception mediated by other (μ- or κ-opioid, cannabinoid, α2-adrenoreceptor) analgesic agents in a warm (55°C) water tail-flick test in mice. Interestingly, i.c.v. treatment with the antisense ODN attenuated antinociception by each analgesic agent. Missense phosphorothioate oligodeoxynucleotide treatment, on the other hand, had no effect on antinociception mediated by these agonists. The antinociceptive response recovered in 6 days after the last antisense ODN injection, indicating a lack of nonspecific tissue damage in the animals. These results suggest a pervasive role for the G protein γ2 subunits in supraspinal antinociception.

KW - Antinociception

KW - Cannabinoid receptor agonist

KW - Clonidine

KW - G protein γ subunit

KW - Guanine nucleotide binding protein

KW - Opioid receptor agonist

UR - http://www.scopus.com/inward/record.url?scp=12844275517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12844275517&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2004.11.062

DO - 10.1016/j.ejphar.2004.11.062

M3 - Article

C2 - 15680258

AN - SCOPUS:12844275517

VL - 508

SP - 93

EP - 98

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -